Study of an experimental drug for MYC-positive advanced cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug (JMBI-001) for people with advanced cancers that have a specific marker called MYC. It aims to see if the drug is safe and effective, possibly shrinking tumors or slowing their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed advanced cancer that has not responded to standard treatments or for which no standard treatment exists.
- For solid tumors: your tumor must have MYC in at least 10% of cells (measured by a special test).
- For lymphoma (a type of blood cancer): you must have tried at least two prior treatments and your tumor must have MYC in at least 40% of cells.
- You must have at least one tumor that can be measured on imaging scans.
- You must be able to swallow tablets and not have severe stomach or intestinal problems that affect absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
This early-phase study tests whether WJB001 capsules can treat advanced solid tumors in adults whose cancer has progressed after standard treatment (or who cannot take standard treatment). It also studies side effects and whether the drug can work for certain tumor types and genetic markers.
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.